Researchers reported that inhibiting IGF-1R can enhance natural killer cell–mediated destruction of myelodysplastic syndrome (MDS) cells. The work described reduced MDS cell proliferation, DNA damage induction, and sensitization to NK cell killing via the MICA/B–NKG2D axis. In preclinical models, the approach ties a metabolic or growth-factor pathway to a concrete immune-recognition mechanism, potentially supporting combination strategies with NK-directed therapies. For MDS, where immune evasion and treatment resistance are ongoing challenges, the findings add a pathway-specific rationale for future translational work.